The current strategy to prevent pregnancy-associated malaria (PAM) comprises intermittent preventive treatment and use of insecticidal nets. The new vaccine, developed by a team of researchers at the University of Copenhagen in Denmark, passed the test by inducing the right antibody response in the blood, according to a study published in the journal Clinical Infectious Diseases. For the study, the researchers examined the effect of the vaccine among 36 people in Germany. "The next step in the process is a phase two clinical trial, which will show whether the vaccine is still safe, but also whether it can prevent disease," said Nielsen. This increases the antibody response.

Source: bd News24 January 11, 2019 12:33 UTC